Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

SK Life Science, Inc. (Industry)
Overall Status
Completed ID

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily by mouth compared with placebo in the treatment of Diabetic Peripheral Neuropathy (DPN).

Condition or Disease Intervention/Treatment Phase
  • Drug: placebo
  • Drug: RWJ-333369 (carisbamate)
Phase 2

Detailed Description

Diabetes mellitus is the most common cause of neuropathy in the Western World, with up to 50% of patients developing neuropathy as a long-term complication of the illness, of whom 10% experience pain. Diabetic neuropathy most often affects the lower extremities and may be severe if inadequately treated. Blood glucose control is a critical treatment element, and several medications have been demonstrated to be effective in treating Diabetic Peripheral Neuropathy (DPN), including antiepileptic drugs, antidepressants and opioid analgesics. These medications are often limited by incomplete pain relief and side effects. This is a randomized (study medication is assigned by chance), double-blind (neither the Investigator or the patient know the name of the assigned study medication), placebo-controlled, crossover, parallel-group, multicenter study to determine the effectiveness and safety of 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks compared with placebo in patients with DPN. The study hypothesis is that 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks will be more effective than placebo in reducing pain due to DPN, as measured by average daily DPN pain scores. Patients will receive 200 mg of RWJ-333369 or matching placebo tablets, given in equally divided doses twice daily by mouth with or without food, for 4 weeks in each of the 2 treatment periods.

Study Design

Study Type:
Actual Enrollment :
132 participants
Intervention Model:
Crossover Assignment
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.
Study Start Date :
Mar 1, 2007
Actual Primary Completion Date :
May 1, 2008
Actual Study Completion Date :
May 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: 002

placebo twice daily for 4 weeks

Drug: placebo
twice daily for 4 weeks

Experimental: 001

RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks

Drug: RWJ-333369 (carisbamate)
200 mg tablet twice daily for 4 weeks

Outcome Measures

Primary Outcome Measures

  1. The mean of the last 7 average daily DPN scores of the first treatment period on days when study drug is taken. [4 weeks]

Secondary Outcome Measures

  1. The means of the last 7 average daily DPN pain scores with no use of rescue medication, the last 7 current daily DPN pain scores, the last 7 maximum daily DPN pain scores, and the last 7 daily sleep interference scores. [4 weeks (2 four-week treatment periods (crossover design)]

Eligibility Criteria


Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Have diabetes mellitus (Type 1 or 2) for longer than 1 year

  • Have clinical evidence of diabetic peripheral neuropathy in the lower extremities for 1 to 5 years before study entry

  • Experienced lower extremity pain due to diabetic peripheral neuropathy on nearly a daily basis for the previous 3 months

  • Have hemoglobin A1c levels less than or equal to 10%

  • Have a stable diabetic treatment regimen, including oral medications for controlling diabetes, insulin, or diet for 3 months before screening

  • Women must be postmenopausal for at least 2 years, sexually abstinent, or if sexually active, be practicing an effective method of birth control, and have a negative serum pregnancy test at screening.

Exclusion Criteria:
  • History of a poor response to 3 or more medications for diabetic peripheral neuropathy (DPN), with poor response is defined as treatment with medications in the following categories of therapy for at least 1 month at therapeutic dosages without at least moderate improvement, as judged by the study doctor: antiepileptic drugs, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors (SNRIs), opioid analgesics, or lidocaine patch

  • currently taking tricyclic antidepressants, Coumadin (warfarin), or continued treatment with an antiepileptic drug for any indication, Note: If taking these medications, to be eligible for the study, they must be tapered and discontinued

  • Prior neurolytic treatment (destruction of nerves by the application of chemicals, heat, or cold), intrathecal pumps, or spinal cord stimulators for DPN pain

  • Use of herbal creams or ointments for pain relief within 48 hours, capsaicin within 6 months, or systemic corticosteroids within 3 months before the baseline period

  • Prior exposure to RWJ-333369 (carisbamate).

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • SK Life Science, Inc.


  • Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
SK Life Science, Inc. Identifier:
Other Study ID Numbers:
  • CR010366
  • 333369NPP2002
First Posted:
Jul 16, 2007
Last Update Posted:
May 1, 2018
Last Verified:
Apr 1, 2018

Study Results

No Results Posted as of May 1, 2018